Each year, the Gold & Silver Shovel Awards offer a snapshot of where deals are landing—and why. This year’s competition was as tight as we’ve seen. States are not just competing on incentives or megasites, but on execution: speed to market, infrastructure readiness, and the ability to navigate an increasingly complex operating environment. We won’t give away the winners here, but what stood out in the judging process was how many projects had to clear higher bars than ever before—on timelines, on certainty, and on long-term viability.
That shift reflects the broader state of site selection in 2026.
Demand remains strong across key sectors, but it is colliding with a more complicated reality. Trade policy continues to evolve in ways that are difficult to model. Supply chains are more diversified, yet still vulnerable to geopolitical shocks. Conflicts abroad are reshaping energy markets and redirecting capital toward defense and strategic industries. At the same time, higher costs of capital and tighter underwriting standards are forcing companies to be more selective, more precise, and less willing to take on risk.
Nowhere is this recalibration more visible than in life sciences. After years of rapid expansion, the sector is entering a more measured phase—one defined by scrutiny around location decisions, workforce alignment, and the long-term functionality of space. Growth is still happening, but the criteria have changed.
What ties all of this together is a narrowing margin for error. Projects are still moving, but only where the fundamentals hold up under pressure. The states and regions succeeding in this environment are the ones that can offer not just opportunity, but confidence.
